CureVac N.V., a biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to €252 million to support the development of its COVID-19 vaccine candidate. In July 2020, CureVac applied for a grant to accelerate the research and development of urgently needed vaccines against SARS-CoV-2.

In addition to the further development of CureVac’s vaccine-candidate against COVID-19, the grant is expected to be used for the rapid expansion of the vaccine production. Payments are contingent on reaching predefined milestones. CureVac expects funding of up to €103 million in 2020 and up to €149 million in 2021.

Franz-Werner Haas, Chief Executive Officer of CureVac, said: “CureVac highly appreciates this significant and important financial support, which is expected to enable us to accelerate the development of our CVnCoV vaccine candidate as well as to increase our manufacturing capacity and, hence, to fight the COVID-19 pandemic. Given the significant costs related to the development of a safe and effective vaccine as well as to the extension of the manufacturing capacity, we believe that this grant can substantially support our efforts to produce and develop a safe and effective vaccine in high volume as quickly as possible.”